Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company that develops mRNA-engineered cell therapies for the treatment of autoimmune diseases. The company uses a proprietary platform to insert messenger RNA into cells, enabling outpatient administration without the need for pre-treatment chemotherapy or viral integration. Its lead product candidate is Descartes-08, an autologous chimeric antigen receptor T-cell therapy in clinical evaluation for conditions such as generalized myasthenia gravis and myositis. The company also developed Descartes-15 for multiple myeloma and explores in-vivo cell engineering technologies. Its primary target patients are individuals living with serious, chronic autoimmune disorders.

The company is headquartered in Frederick, Maryland, where it operates an internal, current good manufacturing practice compliant facility for research, development, and clinical cell therapy production. Cartesian conducts clinical trials across multiple patient cohorts in the United States. Its intellectual property portfolio includes issued and pending patents across various global jurisdictions, including the United States, Canada, Israel, Japan, and South Korea.

Summary of the business section of Cartesian Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 75 full-time employees, 62 of whom are primarily engaged in research and development activities and 13 of whom are primarily engaged in corporate functions.”